(Total Views: 531)
Posted On: 04/10/2021 10:06:40 AM
Post# of 153930
Posted By: nmbr1stckpckr
Saturday, April 10, 2021 08:50:16 AM
Post# of 86141
(Total Views: 251)
Posted On: 04/10/2021 2:44:17 AM
How long has the EFFDA now been sitting on the Company's EUA application? 3 or 4 weeks? Longer? WTEFF!
The conditional EUA application was likely denied. In the PR from April 1st, CYDY said that, “after several weeks of discussions with the FDA,” 4 doses was decided on and a new protocol was submitted. The conditional EUA was submitted during these “several weeks” and I’m sure it was discussed with the FDA along with CD16/17 and the increase in doses.
“announced today that after several weeks of discussions with the U.S. Food and Drug Administration (“FDA”) and analysis of CD12 trial data, and in particular the 82% survival results over placebo after two weeks of leronlimab treatment, with statistically significant p-value of 0.0233, the Company has filed a new protocol to extend treatment to four weeks
https://www.cytodyn.com/newsroom/press-releas...4-doses-of
Saturday, April 10, 2021 08:50:16 AM
Post# of 86141
(Total Views: 251)
Posted On: 04/10/2021 2:44:17 AM
How long has the EFFDA now been sitting on the Company's EUA application? 3 or 4 weeks? Longer? WTEFF!
The conditional EUA application was likely denied. In the PR from April 1st, CYDY said that, “after several weeks of discussions with the FDA,” 4 doses was decided on and a new protocol was submitted. The conditional EUA was submitted during these “several weeks” and I’m sure it was discussed with the FDA along with CD16/17 and the increase in doses.
“announced today that after several weeks of discussions with the U.S. Food and Drug Administration (“FDA”) and analysis of CD12 trial data, and in particular the 82% survival results over placebo after two weeks of leronlimab treatment, with statistically significant p-value of 0.0233, the Company has filed a new protocol to extend treatment to four weeks
https://www.cytodyn.com/newsroom/press-releas...4-doses-of
(3)
(0)
